National, January 29, 2026: Agilus Diagnostics, one of India’s largest diagnostic networks and a subsidiary of Fortis Healthcare Ltd., today announced the installation of the Illumina NovaSeq X at its Mumbai reference laboratory—strengthening India’s capacity for next‑generation sequencing at scale. The launch was attended by Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, Dr. Anand K., Managing Director & CEO, Agilus Diagnostics Ltd., and Mr. Deepak Narang, Chief Operating Officer, Agilus Diagnostics.

Genomic technologies are transforming healthcare by enabling earlier diagnosis and more precise insights into complex diseases. Sequencing today supports a wide range of applications—from rare and inherited disorders to reproductive health, pharmacogenomics, infectious disease surveillance, and large‑scale genome programs.

The NovaSeq X strengthens Agilus Diagnostics’ molecular testing capabilities through high‑throughput sequencing and scalable analytics. Its multi‑omic capacity delivers rapid, high‑resolution results across diverse clinical needs. Through Agilus’ nationwide network, these advanced capabilities become accessible to clinicians and patients in both metro and emerging markets.

Powered by high‑density flow cells and automation, the NovaSeq X enables whole exome sequencing (WES), whole genome sequencing (WGS), and multi‑omic analysis with exceptional speed and accuracy. Deployed for high‑fidelity clinical decision‑making—not just research—it provides physicians with actionable molecular insights and faster turnaround times.

Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said, “Integrating advanced platforms like the Illumina NovaSeq X into clinical diagnostics is a pivotal step for India’s healthcare ecosystem. High‑quality molecular insights are vital not only for oncology but also for diagnosing rare diseases, guiding targeted therapies, and advancing personalized and preventive care. Agilus’ investment brings cutting‑edge science closer to patients and equips clinicians with actionable information to improve outcomes across a broad spectrum of conditions.”

Speaking at the launch, Dr. Anand K., Managing Director & CEO, Agilus Diagnostics, added, “The NovaSeq X marks a major step in our precision diagnostics journey. It strengthens our multi‑omic capabilities across genomics and proteomics, enabling faster, high‑resolution insights that power personalised medicine. This advancement brings us closer to delivering truly predictive and individualized care for patients across India.”

For clinicians and researchers, the enhanced capacity translates into:

• Whole exome and whole genome testing for comprehensive variant detection
• Genetic evaluation of inherited and rare disorders
• Reproductive and maternal health applications, including carrier screening and prenatal testing
• Pharmacogenomic assessments to inform drug response and dosing
• Infectious disease sequencing for pathogen tracking and antimicrobial resistance insights
• Liquid biopsy (ctDNA) analysis and multi‑omic studies for longitudinal disease monitoring and deeper biological understanding

The platform powers Agilus’ expanding portfolio of advanced assays, including proprietary liquid biopsy panels, rare disease testing workflows, reproductive genomics, pharmacogenomic profiling, infectious disease sequencing, and multi‑omic studies. By integrating these outputs into established clinical pathways, Agilus converts complex molecular data into clear and actionable reports for clinicians.

This investment accelerates Agilus Diagnostics’ vision for precision diagnostics and predictive healthcare in India. The NovaSeq X positions Agilus among the few providers ready for future‑focused precision medicine—encompassing population genomics, proteomic innovation, and longitudinal patient monitoring—while ensuring next‑generation diagnostics remain scalable, clinically meaningful, and accessible nationwide.